Companies › Tego Science
1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 1; Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TPX-115 Allogeneic fibroblasts for tendon repair | – | Phase 2 | Partial Thickness Rotator Cuff Tear; Partial Thickness Rotator Cuff Tears; Nasolabial Fold, Hypoplastic | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06533540 | TPX-115 | Phase 1 | Nasolabial Fold, Hypoplastic | Other | Dec 2026 |
| NCT06414005 | TPX-115 | Phase 2 | Partial Thickness Rotator Cuff Tear | Other | Jan 2027 |
| NCT07219654 | TPX-115 | Phase 2 | Partial Thickness Rotator Cuff Tears | Other | May 2027 |
No annotated target.
–
Ascendis Pharma Endocrinology Division Eirion Therapeutics Airway Therapeutics Inotrem BioRestorative Therapies
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.